Skip to main content

Articles

Page 5 of 65

  1. The discovery of functionally relevant KRAS effectors in lung and pancreatic ductal adenocarcinoma (LUAD and PDAC) may yield novel molecular targets or mechanisms amenable to inhibition strategies. Phospholipi...

    Authors: Rodrigo Entrialgo-Cadierno, Cristina Cueto-Ureña, Connor Welch, Iker Feliu, Irati Macaya, Laura Vera, Xabier Morales, Sandra Vietti Michelina, Pietro Scaparone, Ines Lopez, Elodie Darbo, Oihane Erice, Adrian Vallejo, Haritz Moreno, Ainhoa Goñi-Salaverri, David Lara-Astiaso…
    Citation: Molecular Cancer 2023 22:86

    The Correction to this article has been published in Molecular Cancer 2023 22:97

  2. Enhancer of zeste homolog 2 (EZH2), the key catalytic subunit of polycomb repressive complex 2 (PRC2), is overexpressed and plays an oncogenic role in various cancers through catalysis-dependent or catalysis-i...

    Authors: Jianfeng Chen, Jing Han Hong, Yulin Huang, Shini Liu, Jiaxin Yin, Peng Deng, Yichen Sun, Zhaoliang Yu, Xian Zeng, Rong Xiao, Jason Yongsheng Chan, Peiyong Guan, Yali Wang, Peili Wang, Lizhen Liu, Shijun Wen…
    Citation: Molecular Cancer 2023 22:85
  3. Checkpoint blockade immunotherapy, represented by PD-1 or PD-L1 antibody treatment, has been of tremendous success in clinical practice. However, the low clinical response rate and lack of biomarkers for predi...

    Authors: Zongzhi Liu, Xiang Li, Yibo Gao, Jiejie Liu, Yating Feng, Yang Liu, Junyun Wang, Chunmeng Wang, Dongrui Wang, Jie He, Weidong Han, Qian Mei and Yingli Sun
    Citation: Molecular Cancer 2023 22:84
  4. RNA modifications are important regulators of transcript activity and an increasingly emerging body of data suggests that the epitranscriptome and its associated enzymes are altered in human tumors.

    Authors: Vanessa Ortiz-Barahona, Marta Soler, Veronica Davalos, Carlos A. García-Prieto, Maxime Janin, Fernando Setien, Irene Fernández-Rebollo, Joan J. Bech-Serra, Carolina De La Torre, Sonia Guil, Alberto Villanueva, Pei-Hong Zhang, Li Yang, Marco Guarnacci, Ulrike Schumann, Thomas Preiss…
    Citation: Molecular Cancer 2023 22:83
  5. CAR T cell-based therapies have revolutionized the treatment of hematological malignancies such as leukemia and lymphoma within the last years. In contrast to the success in hematological cancers, the treatmen...

    Authors: Lusine Hovhannisyan, Carsten Riether, Daniel M. Aebersold, Michaela Medová and Yitzhak Zimmer
    Citation: Molecular Cancer 2023 22:82
  6. RNA 5-methylcytosine (m5C) modification plays critical roles in the pathogenesis of various tumors. However, the function and molecular mechanism of RNA m5C modification in tumor drug resistance remain unclear.

    Authors: Yueqin Wang, Jingyao Wei, Luyao Feng, Ouwen Li, Lan Huang, Shaoxuan Zhou, Yingjie Xu, Ke An, Yu Zhang, Ruiying Chen, Lulu He, Qiming Wang, Han Wang, Yue Du, Ruijuan Liu, Chunmin Huang…
    Citation: Molecular Cancer 2023 22:81
  7. Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing ...

    Authors: Shengkang Huang, Xinyu Wang, Yu Wang, Yajing Wang, Chenglong Fang, Yazhuo Wang, Sifei Chen, Runkai Chen, Tao Lei, Yuchen Zhang, Xinjie Xu and Yuhua Li
    Citation: Molecular Cancer 2023 22:80
  8. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-018-0844-7.

    Authors: Haihai Liang, Xiaoguang Zhao, Chengyu Wang, Jian Sun, Yingzhun Chen, Guoyuan Wang, Lei Fang, Rui Yang, Mengxue Yu, Yunyan Gu and Hongli Shan
    Citation: Molecular Cancer 2023 22:78
  9. The development of cancer immunotherapeutic strategies relies on the identification and validation of optimal target tumor antigens, which should be tumor-specific as well as able to elicit a swift and potent ...

    Authors: Maria Tagliamonte, Beatrice Cavalluzzo, Angela Mauriello, Concetta Ragone, Franco M. Buonaguro, Maria Lina Tornesello and Luigi Buonaguro
    Citation: Molecular Cancer 2023 22:75
  10. Hypoxia is a hallmark of solid tumors and leads to the metabolic reprogramming of cancer cells. The role of epigenetic regulation between hypoxia and aberrant cholesterol metabolism in colorectal cancer (CRC) ...

    Authors: Li Xiong, Hua-shan Liu, Chi Zhou, Xin Yang, Liang Huang, Hai-qing Jie, Zi-wei Zeng, Xiao-bin Zheng, Wen-xin Li, Zhan-zhen Liu, Liang Kang and Zhen-xing Liang
    Citation: Molecular Cancer 2023 22:72
  11. Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curati...

    Authors: Bo Li, Hui Chen, Shaohua Yang, Feng Chen, Liangliang Xu, Yan Li, Mingzhe Li, Chengming Zhu, Fangyuan Shao, Xinhua Zhang, Chuxia Deng, Leli Zeng, Yulong He and Changhua Zhang
    Citation: Molecular Cancer 2023 22:71
  12. Immunotherapy has emerged to play a rapidly expanding role in the treatment of cancers. Currently, many clinical trials of therapeutic agents are on ongoing with majority of immune checkpoint inhibitors (ICIs)...

    Authors: Yong-Qiang Ao, Jian Gao, Shuai Wang, Jia-Hao Jiang, Jie Deng, Hai-Kun Wang, Bei Xu and Jian-Yong Ding
    Citation: Molecular Cancer 2023 22:70
  13. Extranodal natural killer/T-cell lymphoma (NKTL) is an aggressive type of non-Hodgkin lymphoma with dismal outcome. A better understanding of disease biology and key oncogenic process is necessary for the deve...

    Authors: Jianbiao Zhou, Sabrina Hui-Min Toh, Tze King Tan, Kalpnaa Balan, Jing Quan Lim, Tuan Zea Tan, Sinan Xiong, Yunlu Jia, Siok-Bian Ng, Yanfen Peng, Anand D. Jeyasekharan, Shuangyi Fan, Soon Thye Lim, Chin-Ann Johnny Ong, Choon Kiat Ong, Takaomi Sanda…
    Citation: Molecular Cancer 2023 22:69
  14. The development of head and neck squamous cell carcinoma (HNSCC) is a multi-step process, and its survival depends on a complex tumor ecosystem, which not only promotes tumor growth but also helps to protect t...

    Authors: Yingying Gong, Lisha Bao, Tong Xu, Xiaofen Yi, Jinming Chen, Shanshan Wang, Zongfu Pan, Ping Huang and Minghua Ge
    Citation: Molecular Cancer 2023 22:68
  15. Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in o...

    Authors: Zoufang Huang, Vivek P. Chavda, Rajashri Bezbaruah, Hemant Dhamne, Dong-Hua Yang and Hong-Bing Zhao
    Citation: Molecular Cancer 2023 22:67
  16. HOX transcript antisense intergenic RNA (HOTAIR) is an oncogenic non-coding RNA whose expression is strongly correlated with the tumor grade and prognosis of a variety of carcinomas including breast cancer (BC...

    Authors: Ganji Seeta Rama Raju, Eluri Pavitra, Sai Samyuktha Bandaru, Ganji Lakshmi Varaprasad, Ganji Purnachandra Nagaraju, Rama Rao Malla, Yun Suk Huh and Young-Kyu Han
    Citation: Molecular Cancer 2023 22:65
  17. Diffuse large B-cell lymphoma (DLBCL) exhibits significant genetic heterogeneity which contributes to drug resistance, necessitating development of novel therapeutic approaches. Pharmacological inhibitors of c...

    Authors: Elana Thieme, Nur Bruss, Duanchen Sun, Edward C. Dominguez, Daniel Coleman, Tingting Liu, Carly Roleder, Melissa Martinez, Krystine Garcia-Mansfield, Brian Ball, Patrick Pirrotte, Lili Wang, Zheng Xia and Alexey V. Danilov
    Citation: Molecular Cancer 2023 22:64
  18. Although metastasis is the foremost cause of cancer-related death, a specialized mechanism that reprograms anchorage dependency of solid tumor cells into circulating tumor cells (CTCs) during metastatic dissem...

    Authors: Hyunbin D. Huh, Yujin Sub, Jongwook Oh, Ye Eun Kim, Ju Young Lee, Hwa-Ryeon Kim, Soyeon Lee, Hannah Lee, Sehyung Pak, Sebastian E. Amos, Danielle Vahala, Jae Hyung Park, Ji Eun Shin, So Yeon Park, Han Sang Kim, Young Hoon Roh…
    Citation: Molecular Cancer 2023 22:63

    The Correction to this article has been published in Molecular Cancer 2023 22:135

  19. Molecularly targeted cancer therapies substantially improve patient outcomes, although the durability of their effectiveness can be limited. Resistance to these therapies is often related to adaptive changes i...

    Authors: Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, Hussein Kansou, Sahil Arora, Raj Kumar and Navnath S. Gavande
    Citation: Molecular Cancer 2023 22:62
  20. Kidney, bladder, and prostate cancer are the three major tumor types of the urologic system that seriously threaten human health. Circular RNAs (CircRNAs), special non-coding RNAs with a stabile structure and ...

    Authors: Zi-hao Zhang, Yue Wang, Ya Zhang, Sheng-Feng Zheng, Tao Feng, Xi Tian, Mierxiati Abudurexiti, Zhen-Da Wang, Wen-Kai Zhu, Jia-Qi Su, Hai-Liang Zhang, Guo-Hai Shi, Zi-Liang Wang, Da-Long Cao and Ding-Wei Ye
    Citation: Molecular Cancer 2023 22:61

    The Correction to this article has been published in Molecular Cancer 2023 22:73

  21. Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving tumorigenesis. Therefore, many studies have targ...

    Authors: Ruiwen Ruan, Li Li, Xuan Li, Chunye Huang, Zhanmin Zhang, Hongguang Zhong, Shaocheng Zeng, Qianqian Shi, Yang Xia, Qinru Zeng, Qin Wen, Jingyi Chen, Xiaofeng Dai, Jianping Xiong, Xiaojun Xiang, Wan Lei…
    Citation: Molecular Cancer 2023 22:60
  22. Recent studies suggest that cuproptosis, a novel mode of cell death, may be associated with the development of cancer. However, no studies are showing its role in tumorigenesis, progression, and prognosis. In ...

    Authors: Yan Qin, Yanling Liu, Xiaoyun Xiang, Xingqing Long, Zuyuan Chen, Xiaoliang Huang, Jianrong Yang and Wei Li
    Citation: Molecular Cancer 2023 22:59
  23. In recent years, tumor immunotherapy has made significant progress. However, tumor immunotherapy, particularly immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors), benefits only a tiny proportion of pat...

    Authors: Hao Zhang, Lin Liu, Jinbo Liu, Pengyuan Dang, Shengyun Hu, Weitang Yuan, Zhenqiang Sun, Yang Liu and Chengzeng Wang
    Citation: Molecular Cancer 2023 22:58
  24. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-017-0615-x.

    Authors: Zhuo-yuan Lin, Guo Chen, Yan-qiong Zhang, Hui-chan He, Yu-xiang Liang, Jian-heng Ye, Ying-ke Liang, Ru-jun Mo, Jian-ming Lu, Yang-jia Zhuo, Yu Zheng, Fu-neng Jiang, Zhao-dong Han, Shu-lin Wu, Wei-de Zhong and Chin-Lee Wu
    Citation: Molecular Cancer 2023 22:56
  25. Circular RNAs (circRNAs) can be encapsulated into exosomes to participate in intercellular communication, affecting the malignant progression of a variety of tumors. Dysfunction of CD8 + T cells is the main fa...

    Authors: Zongqiang Hu, Gang Chen, Yingpeng Zhao, Hongqiang Gao, Laibang Li, Yanfeng Yin, Jie Jiang, Li Wang, Yuanyi Mang, Yang Gao, Shengning Zhang, Jianghua Ran and Li Li
    Citation: Molecular Cancer 2023 22:55
  26. Endometrial cancer (EC) is one of the most common gynecologic cancers and its incidence is rising globally. Although advanced EC has a poor prognosis; diagnosing EC at an earlier stage could improve long-term ...

    Authors: Yufei Shen, Wenqing Yang, Jiachen Liu and Yu Zhang
    Citation: Molecular Cancer 2023 22:53

    The Correction to this article has been published in Molecular Cancer 2023 22:76

  27. Inflammation is undoubtedly a hallmark of cancer development. Its maintenance within tumors and the consequences on disease aggressiveness are insufficiently understood.

    Authors: Abdel Jelil Njouendou, Tibor Szarvas, Arnol Auvaker Zebaze Tiofack, Rovaldo Nguims Kenfack, Pamela Derliche Tonouo, Sidonie Noa Ananga, Esther H. M. Dina Bell, Gustave Simo, Jörg D. Hoheisel, Jens T. Siveke and Smiths S. Lueong
    Citation: Molecular Cancer 2023 22:52
  28. Authors: Yongyan Wu, Yuliang Zhang, Xiwang Zheng, Fengsheng Dai, Yan Lu, Li Dai, Min Niu, Huina Guo, Wenqi Li, Xuting Xue, Yunfeng Bo, Yujia Guo, Jiangbo Qin, Yixiao Qin, Hongliang Liu, Yu Zhang…
    Citation: Molecular Cancer 2023 22:51

    The original article was published in Molecular Cancer 2020 19:99

  29. Authors: Jonas Weiße, Julia Rosemann, Lisa Müller, Matthias Kappler, Alexander W. Eckert, Markus Glaß, Danny Misiak, Stefan Hüttelmaier, Wolfgang G. Ballhausen, Mechthild Hatzfeld, Monika Haemmerle and Tony Gutschner
    Citation: Molecular Cancer 2023 22:50

    The original article was published in Molecular Cancer 2021 20:88

  30. Hypoxia develops during the growth of solid tumors and influences tumoral activity in multiple ways. Low oxygen tension is also present in the bone microenvironment where Ewing sarcoma (EwS) – a highly aggress...

    Authors: A. Katharina Ceranski, Martha J. Carreño-Gonzalez, Anna C. Ehlers, Maria Vittoria Colombo, Florencia Cidre-Aranaz and Thomas G. P. Grünewald
    Citation: Molecular Cancer 2023 22:49
  31. The malignant tumor is a multi-etiological, systemic and complex disease characterized by uncontrolled cell proliferation and distant metastasis. Anticancer treatments including adjuvant therapies and targeted...

    Authors: Zhennan Yuan, Yingpu Li, Sifan Zhang, Xueying Wang, He Dou, Xi Yu, Zhiren Zhang, Shanshan Yang and Min Xiao
    Citation: Molecular Cancer 2023 22:48
  32. Cuproptosis was a copper-dependent and unique kind of cell death that was separate from existing other forms of cell death. The last decade has witnessed a considerable increase in investigations of programmed...

    Authors: Jiaming Xie, Yannan Yang, Yibo Gao and Jie He
    Citation: Molecular Cancer 2023 22:46
  33. PIWI proteins have a strong correlation with PIWI-interacting RNAs (piRNAs), which are significant in development and reproduction of organisms. Recently, emerging evidences have indicated that apart from the ...

    Authors: Qun Zhang, Yazhi Zhu, Xinyu Cao, Wenhui Tan, Jianglong Yu, Yaqiong Lu, Ran Kang, Xiaolan Wang and Ermao Li
    Citation: Molecular Cancer 2023 22:45
  34. Cancer development is closely associated with immunosuppressive tumor microenvironment (TME) that attenuates antitumor immune responses and promotes tumor cell immunologic escape. The sequential conversion of ...

    Authors: Chenglai Xia, Shuanghong Yin, Kenneth K. W. To and Liwu Fu
    Citation: Molecular Cancer 2023 22:44
  35. B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer progression. This immune checkpoint molecule is selectively expressed in both tumor cells and immune cells within the tumor micro...

    Authors: Ayechew Adera Getu, Abiye Tigabu, Ming Zhou, Jianrong Lu, Øystein Fodstad and Ming Tan
    Citation: Molecular Cancer 2023 22:43
  36. N6-methyladenosine (m6A) methylation is the most universal internal modification in eukaryotic mRNA. With elaborate functions executed by m6A writers, erasers, and readers, m6A modulation is involved in myriad ph...

    Authors: Xiaoxue Cao, Qishun Geng, Danping Fan, Qiong Wang, Xing Wang, Mengxiao Zhang, Lu Zhao, Yi Jiao, Tingting Deng, Honglin Liu, Jing Zhou, Liqun Jia and Cheng Xiao
    Citation: Molecular Cancer 2023 22:42
  37. Breast cancer is the most common malignant tumor that threatens women's health. Attention has been paid on the study of long- non-coding RNA (lncRNA) in breast cancer. However, the specific mechanism remains n...

    Authors: Yunxiang Zhang, Xiaotong Dong, Xiangyu Guo, Chunsen Li, Yanping Fan, Pengju Liu, Dawei Yuan, Xialin Ma, Jingru Wang, Jie Zheng, Hongli Li and Peng Gao
    Citation: Molecular Cancer 2023 22:41
  38. Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therap...

    Authors: Aritraa Lahiri, Avik Maji, Pravin D. Potdar, Navneet Singh, Purvish Parikh, Bharti Bisht, Anubhab Mukherjee and Manash K. Paul
    Citation: Molecular Cancer 2023 22:40
  39. Hematological malignancies are a highly heterogeneous group of diseases with varied molecular and phenotypical characteristics. SWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin remodeling complexes play sign...

    Authors: Alvaro Andrades, Paola Peinado, Juan Carlos Alvarez-Perez, Juan Sanjuan-Hidalgo, Daniel J. García, Alberto M. Arenas, Ana M. Matia-González and Pedro P. Medina
    Citation: Molecular Cancer 2023 22:39
  40. Ongoing research has revealed that the existence of cancer stem cells (CSCs) is one of the biggest obstacles in the current cancer therapy. CSCs make an influential function in tumor progression, recurrence an...

    Authors: Bo Wu, Xiang Shi, Meixi Jiang and Hongxu Liu
    Citation: Molecular Cancer 2023 22:38

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    91 days submission to accept (Median)

    2023 Usage 
    3,569,666 downloads
    2,070 Altmetric mentions